Predict Prostate Cancer Risk with Leading Accuracy

MPS2 is a comprehensive, personalized biomarker available for patients who have had prior negative biopsies. They often tend to avoid repeat sampling, if indicated. A low risk result provides confidence for observation that both my patient and I can rely on."

PSA screening is one of the most controversial issues in medicine, not only for urologists and clinicians but also and most importantly for our patients. MyProstateScore 2.0 is a wonderful addition to the armamentarium we have available to help us assist our patients when they face an elevated PSA and have a fear of what to do next."

The MPS2 report with the speedometer graphic enables me to easily decipher the report and to better explain the results and my recommendations to patients."

The decision to proceed with a repeat biopsy in the setting of a prior negative sampling can be challenging. Being able to easily show my patient his specific risk of having clinically significant prostate cancer has made these conversations much easier and understandable for my patients.”

Having as much information as possible is important. MPS2 provides an extra unbiased layer to guide us along with the DRE, PSA level, MRI and clinical factors such as age, race and family history. Knowing your patient and his desires with these tools will help with decision making."

Elevated tumor markers are central in my decision making about ordering a biopsy. I use an MRI after deciding to do a biopsy, to determine if the patient will have a standard biopsy or a fusion biopsy."